Acrigen Biosciences

BioTech

Developer of gene technologies designed to improve the efficiency and enhance the safety of CRISPR-Cas-based gene editing. The company’s technologies offer Acr proteins to control the CRISPR-Cas gene editing process to create an improved CRISPR gene, enabling companies to have an editing platform for safe and effective gene therapies.

Address:
626 Bancroft Way
Suite A
Berkeley, CA 94710
Website:
www.acrigen.com